Dr. Todd McAllister, Ph.D. - Co-Founder and CEO of Cytograft Tissue Engineering
Dr. McAllister received his Ph.D. in BioMedical Engineering from the University of California, San Diego. He is the co-founder and CEO of Cytograft Tissue Engineering, Inc. Dr. McAllister has been an early proponent of biological approaches to tissue engineering that do not require synthetic scaffolds. Dr. McAllister has also pioneered a novel business strategy within Regenerative Medicine, taking Cytograft’s lead product, the Lifeline™ Vascular Graft from inception to commercial licensure in Europe on less than $10M in private equity.
Dr. McAllister also served as Co-Director of the Center for Regenerative Medicine at the St. Joseph’s Translational Research Institute in Atlanta, where he oversaw a broader range of cell-based cardiovascular repair technologies. He also serves on several advisory boards, including Lumen, Biocardia, and the Medical University of South Carolina.
Dr. Nicolas L'Heureux, Ph.D. - Co-Founder and CSO of Cytograft Tissue Engineering
Dr. L’Heureux received his Ph.D. in Cell Biology from Laval University in Quebec, Canada and was a post-doctoral AHA fellow in the
Department of Bioengineering at the University of California, San Diego. He is the co-founder and CSO of Cytograft Tissue Engineering, Inc. Dr. L'Heureux invented Tissue Engineering by Self-Assembly (TESA), a novel tissue engineering strategy. He advocates a biological approach to Regenerative Medicine, minimizing the inclusion of synthetic scaffolds and exogenous biomaterials.
Dr. L'Heureux also served as Co-Director of the Center for Regenerative Medicine at the St. Joseph’s Translational Research Institute in Atlanta. As a co-director he oversaw research of cell-based cardiovascular repair technologies.
Dr. Nathalie Dusserre, Ph.D. - Vice President of Manufacturing and Regulatory Affairs of Cytograft Tissue Engineering
Dr. Dusserre received her Ph.D. in Cell Biology and Microbiology from Claude Bernard University in Lyon, France. She was a post-doctoral fellow at the Infectious Diseases Research Center at Laval University in Quebec Canada and a postgraduate researcher in the Department of Bioengineering at the University of California, San Diego.
As the Vice President of Manufacturing and Regulatory Affairs at Cytograft Tissue Engineering, Dr. Dusserre oversees all regulatory aspects of Cytograft's operations. Under her leadership, Cytograft has successfully acquired commercial licensure in Germany and clinical licensure in Poland, Slovakia and the United Kingdom. She is also currently leading interactions with the FDA regarding the recent submission of an IND application for LifeLine™. In addition to her regulatory role, Dr. Dusserre also manages Cytograft's manufacturing and research teams.